Initial Public Offering (IPO)
DanCann Pharma A/S was founded in 2018 and is a Danish pharmaceutical biotechnology company powered by cannabinoids. DanCann Pharma is focused on discovering, developing, manufacturing, and commercializing of novel cannabinoid therapeutics in a broad range of disease areas.
DanCann Pharma is a Danish public limited company incorporated in Denmark and operating under Danish law. The Issuer was founded on 20 March 2018 by CEO Jeppe Krog Rasmussen.
Description of DanCann Pharma as of 30 September 2020 see Prospectus below.
More information about DanCann Pharma is available under Presentations or in the IPO Teasers.
Subscriptions can be made through any of the following platforms: